The past week has surfaced a paradox at the heart of BCI investment. Paradromics completed its first fully implantable wireless system in an ALS patient [S1], and Casey Harrell—an existing implant user—became what MIT Technology Review calls "the first power user" of a speech BCI after three years of independent operation [S2]. Both are celebrated. Both prove the engineering works. Neither answers the question that matters most: *why would a hospital system run a BCI program at scale?*
The distinction is crucial. A power user is an anomaly—someone with institutional support, researcher attention, and years of tuning. The Harrell case is extraordinary precisely because it's rare. Paradromics' trial is a first-in-human milestone, a necessary box to tick, but a single implant in a disease with ~30,000 annual diagnoses in the US tells us nothing about adoption economics or clinical workflow integration. To an investor, it's proof of concept; to a hospital CFO, it's an outlier.
The clinical BCI field has spent a decade celebrating individual successes while avoiding the structural question: what happens when you need to implant the second patient, and the third, and the tenth? Who funds it? Who manages the long-term engagement? What's the reimbursement model? Adaptive deep brain stimulation [S3] shows that closed-loop neurotech *can* improve outcomes measurably—that's not in dispute. But DBS is a known clinical entity with established billing codes, insurance coverage, and surgical infrastructure. BCIs as communication or control devices remain orphaned within healthcare's economic models.
The investment signal is inverted. Right now, the field celebrates when a private company or research institution keeps a patient engaged for years. That shouldn't be a victory—it should be a warning. It signals that BCIs remain dependent on benevolence, not economics. Until a hospital system voluntarily builds a dedicated BCI clinic, staffs it with dedicated neurologists and technicians, and absorbs it into its operating budget, the technology exists in clinical theater, not clinical practice. The implants will get better. The patients will get more impressive. The real test—whether ordinary hospitals in ordinary cities will run ordinary BCIs—remains unwritten.
This matters because scale is where investment value concentrates. A therapy that works brilliantly for one patient has venture upside. A therapy that *should* work for 100,000 patients but can't navigate reimbursement and workflow has public-market risk written across it.